For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $22.85 in the prior trading day, Legend Biotech Corp ADR (NASDAQ: LEGN) closed at $22.98, up 0.57%. In other words, the price has increased by $0.57 from its previous closing price. On the day, 0.68 million shares were traded. LEGN stock price reached its highest trading level at $23.23 during the session, while it also had its lowest trading level at $22.7.
Ratios:
Our goal is to gain a better understanding of LEGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on October 07, 2025, initiated with a Overweight rating and assigned the stock a target price of $40.
On October 08, 2024, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $86.
On June 17, 2024, Truist started tracking the stock assigning a Buy rating and target price of $88.Truist initiated its Buy rating on June 17, 2024, with a $88 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when GenScript Corporation bought 203,586 shares for $30.29 per share.
Casey Patrick John bought 1,000 shares of LEGN for $33,285 on Sep 26 ’25. On Sep 24 ’25, another insider, Huang Ying, who serves as the Officer of the company, bought 1,370 shares for $33.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 4244166144 and an Enterprise Value of 7905979392. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.66 while its Price-to-Book (P/B) ratio in mrq is 4.20. Its current Enterprise Value per Revenue stands at 8.697 whereas that against EBITDA is -43.622.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.11, which has changed by -0.29270548 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $45.30, while it has fallen to a 52-week low of $21.19. The 50-Day Moving Average of the stock is -19.28%, while the 200-Day Moving Average is calculated to be -30.68%.
Shares Statistics:
The stock has traded on average 1.83M shares per day over the past 3-months and 1929040 shares per day over the last 10 days, according to various share statistics. A total of 184.69M shares are outstanding, with a floating share count of 180.91M. Insiders hold about 2.05% of the company’s shares, while institutions hold 44.43% stake in the company. Shares short for LEGN as of 1765756800 were 14410603 with a Short Ratio of 7.88, compared to 1763078400 on 10945914. Therefore, it implies a Short% of Shares Outstanding of 14410603 and a Short% of Float of 14.91.
Earnings Estimates
The dynamic stock of Legend Biotech Corp ADR (LEGN) is currently being evaluated by a team of 7.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.07 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.79 and -$1.64 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is $0.39, with 9.0 analysts recommending between $0.99 and -$0.04.
Revenue Estimates
11 analysts predict $315.49M in revenue for. The current quarter. It ranges from a high estimate of $368.26M to a low estimate of $290M. As of. The current estimate, Legend Biotech Corp ADR’s year-ago sales were $186.52MFor the next quarter, 11 analysts are estimating revenue of $328.9M. There is a high estimate of $378.75M for the next quarter, whereas the lowest estimate is $301.83M.
A total of 14 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.01B, resulting in an average revenue estimate of $1.03B. In the same quarter a year ago, actual revenue was $627.24MBased on 14 analysts’ estimates, the company’s revenue will be $1.54B in the next fiscal year. The high estimate is $1.75B and the low estimate is $1.37B.
